News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
15,234 Results
Type
Article (275)
Company Profile (3)
Press Release (14956)
Section
Business (7743)
Career Advice (4)
Deals (1016)
Drug Development (1513)
Employer Resources (1)
FDA (223)
Job Trends (533)
News (9778)
Policy (409)
Tag
Academia (34)
Allergies (2)
Alliances (403)
Alzheimer's disease (51)
Antibody-drug conjugate (ADC) (10)
Approvals (229)
Artificial intelligence (7)
Autoimmune disease (5)
Automation (1)
Bankruptcy (2)
Best Places to Work (536)
Biosimilars (1)
Biotechnology (1)
Bladder cancer (3)
Breast cancer (15)
Cancer (84)
Cardiovascular disease (1)
Career advice (4)
CAR-T (4)
Cell therapy (8)
Cervical cancer (2)
Clinical research (1291)
Collaboration (11)
Compensation (9)
COVID-19 (44)
CRISPR (1)
C-suite (5)
Cystic fibrosis (2)
Data (115)
Depression (2)
Dermatology (1)
Diabetes (10)
Diagnostics (222)
Digital health (1)
Drug discovery (1)
Duchenne muscular dystrophy (2)
Earnings (7716)
Employer branding (1)
Employer resources (1)
Events (1591)
Executive appointments (3)
FDA (335)
Friedreich's ataxia (1)
Frontotemporal dementia (1)
Funding (1)
Gene editing (2)
Generative AI (1)
Gene therapy (6)
GLP-1 (26)
Government (61)
Guidances (88)
Healthcare (470)
IgA nephropathy (1)
Immunology and inflammation (5)
Indications (4)
Infectious disease (48)
Inflammatory bowel disease (5)
Influenza (5)
Intellectual property (1)
IPO (833)
Job creations (14)
Job search strategy (3)
Kidney cancer (1)
Labor market (2)
Layoffs (8)
Leadership (1)
Legal (36)
Liver cancer (2)
Lung cancer (14)
Lymphoma (11)
Machine learning (1)
Manufacturing (8)
MASH (3)
Medical device (530)
Medtech (535)
Mergers & acquisitions (199)
Metabolic disorders (21)
mRNA (2)
Multiple sclerosis (3)
NASH (2)
Neurodegenerative disease (2)
Neuroscience (62)
NextGen: Class of 2026 (138)
Non-profit (44)
Now hiring (1)
Obesity (9)
Ovarian cancer (3)
Pain (1)
Pancreatic cancer (2)
Parkinson's disease (4)
Patient recruitment (7)
People (479)
Pharmaceutical (1)
Phase 1 (345)
Phase 2 (536)
Phase 3 (555)
Pipeline (426)
Policy (1)
Postmarket research (22)
Preclinical (100)
Press Release (2)
Prostate cancer (2)
Radiopharmaceuticals (5)
Rare diseases (7)
Real estate (21)
Regulatory (347)
Reports (1)
Research institute (30)
Schizophrenia (3)
Sponsored (1)
Startups (23)
Vaccines (15)
Venture capital (2)
Weight loss (5)
Women's health (3)
Date
Today (3)
Last 7 days (9)
Last 30 days (64)
Last 365 days (836)
2026 (228)
2025 (836)
2024 (911)
2023 (1117)
2022 (3698)
2021 (1389)
2020 (1117)
2019 (928)
2018 (773)
2017 (482)
2016 (354)
2015 (554)
2014 (387)
2013 (214)
2012 (187)
2011 (257)
2010 (267)
Location
Africa (2)
Alabama (1)
Arizona (6)
Asia (798)
Australia (130)
California (299)
Canada (83)
China (18)
Colorado (35)
Connecticut (19)
Delaware (13)
Europe (1570)
Florida (63)
Georgia (10)
Idaho (1)
Illinois (25)
Indiana (21)
Iowa (6)
Japan (5)
Kentucky (3)
Louisiana (5)
Maine (13)
Maryland (36)
Massachusetts (191)
Michigan (8)
Minnesota (27)
Missouri (6)
Montana (1)
Nevada (1)
New Hampshire (7)
New Jersey (128)
New York (75)
North Carolina (61)
North Dakota (1)
Northern California (156)
Ohio (11)
Pennsylvania (98)
South America (13)
Southern California (122)
Tennessee (2)
Texas (41)
United States (1245)
Utah (13)
Virginia (2)
Washington State (34)
Wisconsin (5)
15,234 Results for "266".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Theralase(R) Closes $CAN 2.66 Million Financing
April 10, 2026
·
6 min read
Press Releases
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
March 31, 2026
·
6 min read
Drug Development
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration.
April 15, 2024
·
5 min read
Drug Development
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
Neumora Therapeutics, Inc. today announced the initiation of a Phase 1 single ascending dose / multiple ascending dose study evaluating NMRA-266 in healthy adult participants.
November 27, 2023
·
6 min read
Press Releases
Adult Myopia Market Size to Reach USD 266.6 Million by 2035, Impelled by Technological Advancements in Treatment Options
January 22, 2025
·
7 min read
Hyperthermia Cancer Treatment Market Size to Reach US$ 266 Mn by 2030
According to Report Study, the hyperthermia cancer treatment market is predicted to reach US$ 266 Mn by the end of 2030.
August 5, 2022
·
11 min read
Deals
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Dermata Therapeutics, Inc. today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 516,336 shares of the Company’s common stock, having exercise prices of $9.7665 and $32.
May 17, 2024
·
5 min read
Blood Pressure Monitoring Devices Market Size Worth Around US$ 2.66 Bn by 2027
According to Precedence Research, the global blood pressure monitoring devices market size is expected to be worth around US$ 2.66 billion by 2027 and growing at a CAGR 8.56% from 2022 to 2027.
March 14, 2022
·
5 min read
Drug Development
FDA Puts Clinical Hold on Neumora’s Schizophrenia Drug Due to Preclinical Safety Signals
Following cases of convulsions in rabbits in a preclinical study, the FDA has placed a clinical hold on Neumora Therapeutics’ Phase I schizophrenia drug candidate NMRA-266.
April 15, 2024
·
2 min read
·
Tristan Manalac
Genetown
Microbot Medical Announces Closing of $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,209,500 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $2.20 per share of common stock priced at-the-market under Nasdaq rules.
May 24, 2023
·
4 min read
1 of 1,524
Next
